TNFRSF10A抗体;TNFRSF10A Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using TNFRSF10A mouse mAb (green) and negative control (red).    

  
  

TNFRSF10A (Tumor Necrosis Factor Receptor Superfamily Member 10A), also known as TRAIL-R1 or DR4. is a cell surface receptor belonging to the TNF receptor superfamily. It plays a critical role in apoptosis regulation by binding to its ligand TRAIL (TNF-related apoptosis-inducing ligand). Structurally, it contains a cysteine-rich extracellular domain for ligand interaction and a cytoplasmic death domain essential for initiating apoptotic signaling cascades. Activation of TNFRSF10A triggers caspase-dependent apoptosis, making it a key target in cancer research due to TRAIL's selective toxicity toward malignant cells.

Antibodies targeting TNFRSF10A are widely used as research tools to investigate its expression patterns, signaling mechanisms, and therapeutic potential. In experimental settings, these antibodies enable detection of DR4 protein levels via techniques like Western blotting, flow cytometry, or immunohistochemistry. Agonistic anti-TNFRSF10A antibodies mimicking TRAIL activity have shown promise in preclinical studies for inducing apoptosis in cancer cells, particularly when combined with chemotherapy or radiation. Conversely, some antibodies act as antagonists to study resistance mechanisms in tumors. Challenges remain in clinical translation due to variable receptor expression across cancers and acquired resistance through decoy receptors or downstream signaling defects. Current research focuses on optimizing antibody specificity, understanding tumor microenvironment interactions, and developing bispecific antibodies to enhance therapeutic efficacy.